Syncona Ltd GBP · LSE:SYNC
Syncona Ltd GBP — Syncona — Investor Presentation (September 2021)
39 slides from Syncona Ltd GBP's investor presentation, September 2021
Slide 1: Syncona Corporate presentation
Syncona Corporate presentation September 2021 synconaltd.com
Slide 2: Cautionary statement
Cautionary statement This presentation has been prepared and published solely for informational purposes. Nothing contained in this presentation is intended to constitute an offer, invitation or inducement to engage in an investment activity. In this statement, "presentation" means this document tog
Slide 3: Strategy and model
Strategy and model
Slide 4: Building the next generation of healthcare leaders
Building the next generation of healthcare leaders Founded in 2012 by The Wellcome Trust, our purpose is to invest to extend and enhance human life Globally significant Focus on products Founding companies Long-term, scientific research and patients with strategic ambitious capital base ownership Le
Slide 5: Capturing the out return in life science
Capturing the out return in life science +10 years Strategy designed to deliver strong risk adjusted returns for shareholders Syncona Traditional target Venture window Capital target exit window Out return in life science weighted towards late development and product approval: Value • Set companies
Slide 6: Executing a differentiated strategy
Executing a differentiated strategy 10 year targets Capturing the out-return from commercialising Found Build Fund exceptional science 2-3 new portfolio Proactively source Leverage expertise and Scale ambitiously, maintain companies p.a. globally competitive science, track record using Syncona signi
Slide 7: Delivering value through biotech company creation
Delivering value through biotech company creation Building sustainable companies and delivering transformational outcomes for patients Strong track record Building sustainable leaders Patient impact Gross IRR since Capital deployed since 2012 Patients benefitted by the first Syncona 27% inception (2
Slide 8: Market context and our portfolio
Market context and our portfolio
Slide 9: The promise of precision medicine
The promise of precision medicine Enables faster development, smaller, more capital efficient clinical trials and targeted commercial roll-out 30-60% A traditional drug may only be 30- 60% effective* ‒ Traditional drug development can lead to ineffective drug development; it assumes all patients res
Slide 10: Third Wave therapies have strong momentum
Third Wave therapies have strong momentum Syncona has established a leadership position in gene and cell therapy “First Wave’’ 13 +20% Third Wave therapies Increase in advanced 1950’s taken into the clinic by Small Molecule drugs, “Second Wave’’ therapy medicinal Syncona founded trials in UK between
Slide 11: A balanced portfolio with a strong pipeline
A balanced portfolio with a strong pipeline 11 portfolio companies diversified across the development cycle, with 5 at clinical stage Pre-clinical Phase 1/2 Phase 3/Pivotal BLA* Launch % of portfolio** Cell therapy 2023 CAR-T Neo-antigens T-regulatory cells 36% Macrophage cells T cell receptors Gene
Slide 12: Our approach to funding
Our approach to funding
Slide 13: Balance sheet strength is strategic and a key differentiator
Balance sheet strength is strategic and a key differentiator Life science companies requires significant Strong capital base is central to delivery of strategy and provides competitive capital as they scale advantage - Founding investors have the best ability to set strategy Syncona capital base - L
Slide 14: Competing on a global scale requires significant capital
Competing on a global scale requires significant capital £m** 900 Syncona 3rd Party 800 - £2bn* raised by Syncona companies - £830m committed by Syncona 700 - Strong balance sheet enables us to invest in our 600 companies over the long-term 500 - As companies scale and enter the clinic significant 4
Slide 15: An evolving focus on our financing approach to deliver strategy
An evolving focus on our financing approach to deliver strategy Syncona focuses on fundamentals and long-term delivery of products Ongoing progress in optimising financing approach − Listing on NASDAQ provides our companies with the capital they require as they scale − Listed holdings bring volatili
Slide 16: Financials and outlook
Financials and outlook
Slide 17: Funded to deliver upcoming milestones
Funded to deliver Clinical stage Pre-clinical stage Drug discovery upcoming milestones 31 March Net invested/ FX 30 June 2021 NAV of £1,200.4m, 178.9p per share; capital Portfolio Ownership* 2021 value £m (Fair returned the period Valuation change in move ment value £m (Fair Valuation basis (Fair po
Slide 18: Portfolio company outlook
Portfolio company outlook Strong momentum in the portfolio with near term catalysts Company Status of pipelines Next steps Three programmes across four clinical trials - Progress pivotal study AUTO1 / Adult ALL, data update in CY2022 - Publish clinical data on AUTO1/22 / paediatric ALL in Q4 CY2021
Slide 19: Summary
Summary Syncona platform creates value from the commercialisation of life science innovation CURRENT PORTOLIO ROLLING 10 YEAR TARGETS Strong track record with 17 2 Companies sold since foundation, portfolio funded to deliver next aggregate 6.2x multiple on capital invested** 15-20 key milestones Por
Slide 20: Appendix 1 – Syncona platform
Appendix 1 – Syncona platform
Slide 21: An expert multi-disciplinary team
An expert multi- Our unique skill set disciplinary team Scientific Commercial Company creation Investment Investment committee Nigel Keen Martin Murphy 1,2 Chris Hollowood 1 Co-founder and Chairman Co-founder and CEO CIO FIET, FCA PhD PhD Purespring ‒ Commercial and company creation ‒ Scientific, co
Slide 22: Sourcing technology in growing areas has led to multiple Syncona companies
Sourcing technology in growing areas has led to multiple Syncona companies and investments \\\\ \\\\ \\\\ \\\\\\\\\\\\\\\\\ \\\\\\\\\\\\\\\\\ \\\\\\ Cell therapy: T-cell biology & Gene therapy: companies covering the Radiotherapy companies immuno-oncology key tissue compartments covering key cell ty
Slide 23: Syncona platform: a growing competitive advantage
Syncona platform: a growing competitive advantage Platform enables rapid translation of basic scientific research into companies with the potential to be global leaders - Ability to identify a compelling new - Increased capability, expertise and network to area of science where a support company bui
Slide 24: Appendix 2 – Sustainability
Appendix 2 – Sustainability
Slide 25: Our approach to sustainability
Our approach to sustainability Read our Sustainability Syncona is committed to managing its business and portfolio sustainably and responsibly. Report at synconaltd.com Our Sustainability Policy focuses on four key areas that align with the UN Sustainable Development Goals (SDGs) Responsible Inspiri
Slide 26: A responsible investor and partner
A responsible investor and partner Seeking to integrate the management of sustainability issues into our investment process and across our portfolio Responsible investor and partner 1 Governance and compliance Initial screen 2 Good R&D Practice − Focus on transformational impacts for patients We pla
Slide 27: The Syncona Foundation
The Syncona Foundation Supporting excellent charities that are meeting pressing needs within society, particularly those that are related to healthcare systems Focused on cancer, neuro-degenerative diseases, £36.4m Donations since 2012 gene therapy. Alongside other health and society related areas i
Slide 28: Appendix 3 – Portfolio companies
Appendix 3 – Portfolio companies
Slide 29: Autolus Therapeutics
Autolus Therapeutics Applying a broad range of technologies to build Investment thesis a pipeline of precisely targeted T cell therapies - No CAR-T therapy approved for adult designed to better recognise and attack cancer ALL patients Board Seat 1 (as Chair) Key management team - AUTO1 has a differe
Slide 30: Freeline Therapeutics
Freeline Therapeutics Seeking to deliver constant high protein expression Key management team Investment thesis levels with curative potential across a broad pipeline of Michael Parini, CEO (former Chief Administrative, Legal and - To deliver therapies for a broad pipeline systemic diseases; opportu
Slide 31: Gyroscope Therapeutics
Gyroscope Therapeutics Global clinical-stage company developing gene therapy Investment thesis beyond rare disease. Developing differentiated pipeline Key management team - Seeking to take application of gene of rAAV gene therapies targeting genetic variants in the therapy beyond rare diseases to tr
Slide 32: Achilles Therapeutics
Achilles Therapeutics Key management team Differentiated cell therapy approach targeting Iraj Ali, Chief Executive (former Syncona Partner) Investment thesis solid tumours utilising bioinformatics and Tumour Karl Peggs, Founder and Chief Medical Officer - TILs have shown convincing efficacy in Infil
Slide 33: Anaveon Therapeutics
Anaveon Therapeutics Exploiting the power of cytokines to orchestrate Investment thesis immune responses by using protein - Developing a selective IL-2 agonist with engineering with the potential to create to improved administration and toxicity create safe and effective treatments for various burde
Slide 34: SwanBio Therapeutics
SwanBio Therapeutics Developing leading-edge gene therapies to Investment thesis deliver dramatic clinical efficacy for the - Gene therapy has the potential to be treatment of neurological diseases transformational in neurology - Lead programme targeting AMN*, an Board Seat 2 (inc. Chair) Key manage
Slide 35: Quell Therapeutics
Quell Therapeutics Engineered cell therapy company addressing Investment thesis Key management team immune dysregulation Iain McGill, CEO (formerly on the Executive Committee and as Head of - Current standard of care for prevention Europe and Rest of World for Jazz Pharmaceuticals) of solid organ tr
Slide 36: OMass Therapeutics
OMass Therapeutics Building a differentiated small molecule Investment thesis portfolio based on a unique drug discovery - Opportunity to develop differentiated platform leveraging native Mass Spectrometry. small molecule drugs leveraging a world-leading Native Mass Key management team Spectrometry
Slide 37: Resolution
Resolution Developing macrophage cell therapies to Investment thesis repair inflammatory organ damage, including - An opportunity to create the leading treatment of end-stage chronic liver disease. inflammation-focused macrophage cell therapy business, focusing initially on Key management team treat
Slide 38: Purespring
Purespring Advancing gene therapies for the treatment of Investment thesis chronic renal diseases that are currently poorly - A number of chronic kidney diseases addressed with existing treatments are poorly addressed by existing therapies, which are primarily based Key management team around the lo
Slide 39: Neogene
Neogene Building a differentiated small molecule Investment thesis portfolio based on a unique drug discovery - The company is developing an platform leveraging native Mass Spectrometry. engineered T Cell Receptor (TCR) therapeutic approach for solid tumours based on a patient’s own Key management t